Nordic Tech House to invest in stem cell company NextCell Pharma
NextCell Pharma (NXTCL), traded at AktieTorget, announces that a collaboration with Nordic Tech House has been agreed upon where Nordic Tech House will invest in NXTCL and develop the digital presence of NXTCL and Cellaviva.
The two-year agreement means that Nordic Tech House will be responsible for the total digital presence of NXTCL, with a specific focus on the family stem cell saving service that is offered to expectant parents through the Cellaviva trademark. Isabella Löwengrip, one of the co-owners of Nordic Tech House, will as influencer, mother, entrepreneur and investor increase the stem cell awareness in Sweden.
The agreement states that Nordic Tech House will receive a total of 2 MSEK in NXTCL shares, which will be transferred to Nordic Tech House semi-annually in arrears. The share price is determined at the average valuation of the closing price of NXTCL's stock 10 trading days before 13 March. Nordic Tech House commits itself to a lock-up clause not to divest the shares during the 2 year the agreement.
"It is a privilege to be able to work together with Sweden's leading stem cell company and use my channels to inform women about the possibility to save their child's stem cells from birth,” says Isabella Löwengrip, co-founder and shareholder of Nordic Tech House. "Weekly I reach 400,000 parents of toddlers, so I know there are many parents willing to maximize the opportunity to give their children a good health throughout life. Therefore, I have chosen to invest in NXTCL and Cellaviva.
"NextCell Pharma is interesting both for collaborative and investment purposes, our common goal is to accelerate the growth of Cellaviva and reach out to new customers," says Viktor Lundquist, CEO of Nordic Tech House. "There are good conditions for a very valuable development of Cellaviva and NXTCL's stem cell product, ProTrans, which is already in clinical trials. "
"We are looking forward to working with Nordic Tech House's professional team, improving our digital platforms and raising awareness regarding birth as a unique opportunity to obtain stem cells, an offer available through Cellaviva’s biobanking facility," says Dr. Mathias Svahn, CEO of NextCell Pharma AB.
This information is the information that NextCell Pharma AB is required to disclose under the EU Market Abuse Regulation. The information was provided by the below contact person for publication on March 14th, 2018.
Stay up to date with the latest development in NextCell Pharma
LinkedIn: https://www.linkedin.com/company/15255207/
Twitter: https://twitter.com/NextCellPharma
For more information about NextCell Pharma AB, please contact:
Mathias Svahn, CEO
Leo Groenewegen, CFO
Phone: 08-735 5595
E-mail: info@nextcellpharma.com
About NextCell Pharma AB:
Stem cells are expected to change the way how many of today's life-threatening diseases are treated. NextCell
Pharma AB develops ProTrans™, a drug candidate consisting of stem cells for the primary treatment of autoimmuneand inflammatory diseases as well as for use in kidney transplants. ProTrans™ consists of selected stem cells derived from the umbilical cord tissue with NextCell Pharma AB's proprietary method. In addition, the company has a service called Cellaviva, Sweden's first and only IVO-approved stem cell bank for the family-saving of stem cells from umbilical cord blood and umbilical cord tissue.